logo
  

Stock Alert: EyeGate Pharmaceuticals Soars Above 75%

Shares of EyeGate Pharmaceuticals, Inc. (EYEG) are surging more than 75% Monday morning after the company announced the acquisition of Panoptes Pharma, a privately held clinical-stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases.

With this acquisition, PP-001, a next-generation, non-steroidal, immuno-modulatory, small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with potential best-in-class picomolar potency, gets added to EyeGate's pipeline.

Panoptes has achieved major clinical milestones and has shown that PP-001 is efficacious and safe as an intravitreal injection (PaniJect) in non-infectious posterior segment uveitis patients.

Under the terms of the agreement, Panoptes will become a wholly owned subsidiary of EyeGate.

The consideration from EyeGate is $4 million in EyeGate common stock, EyeGate preferred stock and cash.

After 18 months, an additional $1.5 million will be issued in EyeGate preferred stock, subject to adjustments for post-closing working capital or indemnification obligations.

The deal also includes $4.75 million in cash or shares contingent upon Panoptes achieving certain clinical milestones.

"The acquisition of Panoptes propels the EyeGate pipeline forward to include a de-risked clinical-stage candidate with broad potential across a diverse range of ocular, autoimmune and neurological indications," said Stephen From, Chief Executive Officer of EyeGate.

EYEG, currently at $6.32, has been trading in the range of $3.20- $12.89 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Editors Pick
Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Video streaming giant Netflix Inc. announced the availability of a variety of mobile games. Players can download the games directly from the Netflix mobile app. The new games include Dragon Up (East Side Games), Moonlighter (11 Bit Studios), Townsmen - A Kingdom Rebuilt (HandyGames), and Exploding Kittens - The Game (Exploding Kittens Digital).
Follow RTT